NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 15.5% and is now trading at $13.89. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Cytokinetics.

Cytokinetics, Inc. (NASDAQ:CYTK) posted its earnings results on Tuesday, March, 3rd. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.08. The biopharmaceutical company had revenue of $5.21 million for the quarter, compared to analyst estimates of $7.19 million. Cytokinetics had a negative return on equity of 10,351.99% and a negative net margin of 452.92%. View Cytokinetics' earnings history.

Cytokinetics issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, March, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18-22 million, compared to the consensus revenue estimate of $28.03 million.

6 brokers have issued 12-month target prices for Cytokinetics' shares. Their forecasts range from $20.00 to $30.00. On average, they expect Cytokinetics' share price to reach $23.67 in the next twelve months. This suggests a possible upside of 70.4% from the stock's current price. View analysts' price targets for Cytokinetics.

Media stories about CYTK stock have been trending very negative on Friday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytokinetics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutCytokinetics.

Cytokinetics saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 7,830,200 shares, a drop of 6.1% from the February 27th total of 8,340,000 shares. Based on an average daily trading volume, of 749,000 shares, the days-to-cover ratio is currently 10.5 days. Approximately 14.4% of the shares of the stock are short sold. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include GW Pharmaceuticals PLC- (GWPH), Agios Pharmaceuticals (AGIO), PTC Therapeutics (PTCT), ChemoCentryx (CCXI), Allakos (ALLK), Amicus Therapeutics (FOLD), PPD (SDGR), Alkermes (ALKS), Deciphera Pharmaceuticals (DCPH), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), ArQule (ARQL), Arena Pharmaceuticals (ARNA), Uniqure (QURE) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.09%) and Sanders Morris Harris LLC (0.02%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View institutional ownership trends for Cytokinetics.

CYTK stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, and State of Alaska Department of Revenue. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $13.89.

Cytokinetics has a market capitalization of $825.90 million and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe. View additional information about Cytokinetics.

The official website for Cytokinetics is http://www.cytokinetics.com/.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]